BDBradley M. Dennis

Bradley M. Dennis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bradley M. Dennis has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury

    by Jennifer Beavers, Mary Katherine Cella Shultz, Leanne Atchison, Cara Lwin, Dandan Liu, Silky Chotai, Andrew J. Medvecz, Robel Beyene, Michael C. Smith, Bradley M. Dennis, et al.

    Background: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB). Methods: A retrospective, propensity score‐weighted study was conducted in adult patients with a TBI admitted to an American College of Surgeons Certified Level I Trauma Center. The NSAID group included patients who received at least one dose of an NSAID within 14 days of injury while admitted. The control group included patients who did not receive NSAIDs. The primary end point was incidence of a clinically significant PIB (decrease in the Glasgow Coma Score (GCS) > 2 and an increased or new ICH). Secondary outcomes included need for additional neurosurgical intervention and PIB on imaging regardless of GCS change. Results: 978 patients were included: 284 in the NSAID group and 694 in the control group. Most patients had an Abbreviated Injury Score head > 2 (88%) and a subdural hematoma (57%). Fifty‐two percent of patients had a mixed bleed. A clinically significant PIB occurred in 0.35% in the NSAID group and 1.2% in the control group (Hazards Ratio 0.1, 95% Confidence Interval 0.01–0.82, p = 0.032). There was no difference in additional neurosurgical operations or PIB regardless of GCS change. In the NSAID group, there was no significant difference in time from admission to NSAID administration between patients who experienced a PIB and those who did not have a PIB (1.9 days vs. 4.7 days, respectively, p = 0.06). Conclusion: In this single‐center, retrospective, propensity score‐weighted study, NSAIDs were not associated with an increased risk of clinically significant PIB in patients with acute TBI when administered within 14 days of injury. NSAIDs appear safe in the acute phase post‐TBI. Prospective studies are needed to validate our results.

  • Open Access

    Does mean arterial pressure augmentation improve neurological recovery of blunt spinal cord injuries: an EAST multicenter trial

    by Aimee LaRiccia, Stephanie Doris, Bhairav Shah, Tanisha Kashikar, Erik Teicher, Lindsey Perea, Jennifer Huber, Malia Eischen, H Akin Erol, Michael Steven Farrell, et al.

    Background: Treatment of blunt traumatic spinal cord injuries (SCIs) often includes maintaining elevated mean arterial blood pressures (MAP) to enhance perfusion to the spinal cord. Optimal hyperperfusion protocols and treatment algorithms have yet to be delineated due to a paucity of large volume prospective studies. This study aims to identify predictors of neurological improvement in American Spinal Injury Association (ASIA) impairment score following blunt SCI. Study design: Prospective (January 10, 2021 to June 1, 2023) multicenter study included blunt SCI patients age >18 with complete neurological examination documented on hospital arrival. Patients were divided into two groups: neurological improvement and no improvement, based on their change in ASIA score from arrival to hospital discharge. Results: A total of 19 centers contributed 222 patients of those, 164 had pre-ASIA and post-ASIA scores. The ASIA improvement group had 36 patients (22%). There was no statistical difference in the median percentage of time patients spent at a MAP >85 mm Hg during treatment 80.7% (IQR 63.6, 93.4) no improvement vs 83.6% (IQR 70.1, 93.0) in the improvement, (p=0.87). There was no difference in the median duration of MAP treatment in hours between the groups (95.6 hours (IQR 62.55, 113.48) in the no improvement group versus 96 (IQR 72, 113.5) (p=0.40) in the improvement group). Conclusions: Overall, 22% of all blunt SCI patients saw an improvement in their ASIA score. Adherence to and length of MAP augmentation was not a statistically significantly different between groups. Level of evidence: Level IV Therapeutic/Care Management.


  • Military–civilian partnerships

    by Robel T. Beyene, Bradley M. Dennis, Joshua P. Smith


  • Open Access

    Incorrect blood typing and mis‐transfusion due to low‐titer group O whole blood resuscitation

    by Miriam Brown, Deva Sharma, Kaycie Atchison, Bradley M. Dennis, Erika Hall, Angela Mueller, Christine Schaeffer, Jessica E. Schucht, Jill R. Streams, Toufik Tahiri, et al.

    Background: Resuscitation strategies for massive hemorrhage increasingly involve the use of low‐titer group O whole blood (LTOWB) due to evidence suggesting improved patient outcomes. However, the potential risk of incorrect ABO typing following LTOWB administration, possibly leading to mis‐transfusion, remains insufficiently explored. This case series aims to highlight the potential risk of ABO mistyping associated with LTOWB transfusions in trauma settings.Study Design and Methods: We retrospectively reviewed three cases involving trauma patients who received LTOWB transfusions at a high‐volume urban Level 1 Trauma Center. ABO and RhD typing were performed using automated column agglutination technology (Ortho ID‐MTS™), and discordant typing results prompted further investigations to confirm patients' true ABO type and identify mis‐transfusions.Results: All three patients initially received LTOWB due to traumatic hemorrhage. Initial ABO typing after LTOWB administration incorrectly identified the patients as group O. Follow‐up investigations later confirmed their true blood types as group A. Two cases resulted in subsequent inadvertent transfusions of ABO‐incompatible plasma. Although no severe adverse clinical outcomes occurred, these events were reported to regulatory bodies as biologic product deviations.Discussion: Our findings highlight a rare but clinically significant risk of ABO typing errors following LTOWB transfusion, primarily due to contamination of patient samples with donor blood. Such errors carry the potential for acute hemolytic reactions, underscoring the critical need for strict adherence to sampling protocols. Whenever possible, ABO typing should be performed prior to LTOWB administration, and samples should be drawn from a site contralateral to the transfusion.

  • Open Access

    Computed tomography scanning is feasible in select patients with REBOA catheter deployment

    by Michael C. Smith, Andrew J. Medvecz, Melissa R. Smith, Jill R. Streams, Bradley M. Dennis


  • Open Access

    2893 B. Effect of Cefepime versus Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection: A Randomized Clinical Trial

    by Edward Qian, Jonathan Casey, Adam Wright, Li Wang, Matthew Shotwell, Justin Siemann, Mary Lynn Dear, Joanna Stollings, Bradley Lloyd, Tanya Marvi, et al.

    Cefepime and piperacillin-tazobactam are commonly administered to hospitalized adults for empiric treatment of infection. Although piperacillin-tazobactam has been hypothesized to cause acute kidney injury and cefepime has been hypothesized to cause neurological dysfunction, their comparative safety has never been evaluated in a randomized trial. We aimed to determine whether choice between piperacillin-tazobactam and cefepime affects risks of acute kidney injury or neurological dysfunction. The Antibiotic Choice On ReNal outcomes (ACORN) study was a pragmatic randomized trial comparing piperacillin-tazobactam versus cefepime, conducted from November 2021 to October 2022; patient follow up concluded on November 4, 2022. Eligible patients were adults in the emergency department or medical intensive care unit for whom a clinician initiated anti-pseudomonal antibiotics within 12 hours of presentation to the hospital. Patients were randomized in a 1:1 ratio to cefepime or piperacillin-tazobactam. The primary outcome was the highest stage of acute kidney injury or death by day 14, measured on a 5-level ordinal scale ranging from no acute kidney injury to death. The two secondary outcomes were the incidence of major adverse kidney events at day 14 and number of days alive and free of delirium and coma within 14 days. Flow of participants through the trial. Antibiotic receipt by group Effect Modification of the Primary and Secondary Outcomes. For each subgroup, the effect of cefepime vs piperacillin-tazobactam is shown for the primary outcome of highest stage of acute kidney injury (AKI) or death and the secondary outcomes of major adverse kidney events at 14 days (MAKE14) and the number of days alive and free of delirium and coma within14 days. For the renal outcomes, odds ratios less than 1.0 indicate a better outcome in the cefepime group compared to the piperacillin-tazobactam group. For the outcome days alive and free of delirium and coma, an odds ratio greater than 1.0 indicates a better outcome in the cefepime group compared to the piperacillin-tazobactam group. Baseline Coma was added post hoc. KRT is kidney replacement therapy. Among hospitalized adults in this randomized trial, treatment with piperacillin-tazobactam did not increase the incidence of acute kidney injury or death. Treatment with cefepime resulted in more neurological dysfunction Jonathan Casey, MD. MSc, Fisher and Paykel: Travel grant Jesse Wrenn, MD, PhD, Bristol Myers Squibb: Grant/Research Support Matthew Semler, MD, MSc, Baxter International: Advisor/Consultant Todd Rice, MD, MSc, Cumberland Pharmaceuticals: Advisor/Consultant|Cytovale Inc: Advisor/Consultant|Sanofi: Advisor/Consultant

  • Vascular imaging immediately after tourniquet removal does not increase vasospasm risk

    by Eric H. Mace, Amelia W. Maiga, Robel T. Beyene, Michael C. Smith, Jill R. Streams, Allan B. Peetz, Bradley M. Dennis, Oscar D. Guillamondegui, Stephen P. Gondek


  • Open Access

    Identifying temporal variations in burn admissions

    by Robel T. Beyene, David P. Stonko, Stephen P. Gondek, Jonathan J. Morrison, Bradley M. Dennis

    Background: Variations in admission patterns have been previously identified in non-elective surgical services, but minimal data on the subject exists with respect to burn admissions. Improved understanding of the temporal pattern of burn admissions could inform resource utilization and clinical staffing. We hypothesize that burn admissions have a predictable temporal distribution with regard to the time of day, day of week, and season of year in which they present. Study design: A retrospective, cohort observational study of a single burn center from 7/1/2016 to 3/31/2021 was performed on all admissions to the burn surgery service. Demographics, burn characteristics, and temporal data of burn admissions were collected. Bivariate absolute and relative frequency data was captured and plotted for all patients who met inclusion criteria. Heat-maps were created to visually represent the relative admission frequency by time of day and day of week. Frequency analysis grouped by total body surface area against time of day and relative encounters against day of year was performed. Results: 2213 burn patient encounters were analyzed, averaging 1.28 burns per day. The nadir of burn admissions was from 07:00 and 08:00, with progressive increase in the rate of admissions over the day. Admissions peaked in the 15:00 hour and then plateaued until midnight (p0.05), though weekend admissions skewed slightly later (p = 0.025). No annual, cyclical trend in burn admissions was identified, suggesting that there is no predictable seasonality to burn admissions, though individual holidays were not assessed. Conclusion: Temporal variations in burn admissions exist, including a peak admission window late in the day. Furthermore, we did not find a predictable annual pattern to use in guiding staffing and resource allocation. This differs from findings in trauma, which identified admission peaks on the weekends and an annual cycle that peaks in spring and summer.


  • Assessment of safety and effectiveness of non-neurosurgical management for minimal traumatic brain injury (TBI)

    by Jeffrey W. Chen, Aaron Yengo-Kahn, Silky Chotai, Akshay Bhamidipati, Candice Smith, Philip Davis, Rebecca A. Reynolds, Mary Peyton Boyd, Tyler W. Barrett, Elizabeth S. Compton, et al.


  • The choices we make: Ethical challenges in trauma surgery

    by Pranit N. Chotai, Marie D. Kuzemchak, Mayur B. Patel, Catherine Hammack-Aviran, Bradley M. Dennis, Stephen P. Gondek, Oscar D. Guillamondegui, Keith G. Meador, Kenneth A. Wallston, Heidi Chen, et al.